AC Immune (NASDAQ:ACIU – Get Free Report) issued its earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03, Zacks reports.
AC Immune Stock Up 0.2 %
Shares of ACIU traded up $0.01 during mid-day trading on Thursday, reaching $2.33. The company had a trading volume of 39,816 shares, compared to its average volume of 329,218. The stock has a 50 day moving average of $2.64 and a two-hundred day moving average of $2.99. The stock has a market capitalization of $230.04 million, a P/E ratio of -5.07 and a beta of 1.23. AC Immune has a 52-week low of $2.19 and a 52-week high of $4.98.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of AC Immune in a report on Friday, November 15th.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Stories
- Five stocks we like better than AC Immune
- 3 Grocery Stocks That Are Proving They Are Still Essential
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- 3 Best Fintech Stocks for a Portfolio Boost
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
- Which Wall Street Analysts are the Most Accurate?
- Is a Bottom Finally Forming in Rocket Lab Stock?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
